Shukun Technology
Total Raised
$247.65MInvestors Count
19Deal Terms
4Investments
2Shukun Technology Funding, Shukun Technology Valuation & Shukun Technology Revenue
6 Fundings
Shukun Technology's latest funding round was a Series D for $108.09M on August 16, 2021.
Shukun Technology's valuation in December 2020 was $600M.
Shukun Technology's latest post-money valuation is from August 2021.
Sign up for a free trial to see Shukun Technology's valuations in August 2021, August 2020, June 2020 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
---|---|---|---|---|---|---|
8/16/2021 | Series D | $108.09M | 6 | |||
12/28/2020 | Series C | ▲$600M | ||||
8/31/2020 | Series B - III | |||||
6/15/2020 | Series B - II | |||||
2/18/2019 | Series B |
Date | 8/16/2021 | 12/28/2020 | 8/31/2020 | 6/15/2020 | 2/18/2019 |
---|---|---|---|---|---|
Round | Series D | Series C | Series B - III | Series B - II | Series B |
Amount | $108.09M | ||||
Investors | |||||
Valuation | ▲$600M | ||||
Revenue | |||||
Sources | 6 |
Shukun Technology Deal Terms
4 Deal Terms
Shukun Technology's deal structure is available for 4 funding rounds, including their Series D from August 16, 2021.
Round | Series D | Series C | Series B - III | Series B - II |
---|---|---|---|---|
Funding Date | ||||
Pre-Money Valuation | ||||
Post-Money Valuation | ||||
Amount Raised | ||||
Shares Authorized | ||||
Issuance Price | ||||
Dividend Rate | ||||
Liquidation Preferences | ||||
Liquidation Price | ||||
Participation | ||||
Conversion Price | ||||
Anti Dilution | ||||
General Voting | ||||
Board Voting | ||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series D | |||||||||||||||
Series C | |||||||||||||||
Series B - III | |||||||||||||||
Series B - II |
Shukun Technology Investors
19 Investors
Shukun Technology has 19 investors. Marathon Venture Partners invested in Shukun Technology's Series D funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
---|---|---|---|---|---|---|
7/3/2018 | 8/16/2021 | 4 Series A, Series B (2019), Series C (2020), Series D (2021) | Venture Capital | China | ||
12/28/2020 | 8/16/2021 | 2 Series C, Series D (2021) | Venture Capital | China | ||
8/16/2021 | 8/16/2021 | 1 Series D | Private Equity | China | ||
Private Equity | China | |||||
Corporation | New York |
First funding | 7/3/2018 | 12/28/2020 | 8/16/2021 | ||
---|---|---|---|---|---|
Last Funding | 8/16/2021 | 8/16/2021 | 8/16/2021 | ||
Investor | |||||
Rounds | 4 Series A, Series B (2019), Series C (2020), Series D (2021) | 2 Series C, Series D (2021) | 1 Series D | ||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Private Equity | Private Equity | Corporation |
Location | China | China | China | China | New York |
Shukun Technology Investments
2 Investments
Shukun Technology has made 2 investments. Their latest investment was in CureFun as part of their Seed VC - III on April 4, 2022.
Shukun Technology Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/8/2022 | Seed VC - III | CureFun | Yes | 1 | ||
1/25/2022 | Series A |
Date | 4/8/2022 | 1/25/2022 |
---|---|---|
Round | Seed VC - III | Series A |
Company | CureFun | |
Amount | ||
New? | Yes | |
Co-Investors | ||
Sources | 1 |
You May Also Like
Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

Ultromics is a global health technology company that provides autonomous echocardiography analysis through AI solutions – empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.
RadNet is a national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. The company has a network of 293 owned and/or operated outpatient imaging centers.

Quibim, a company with its headquarters in Valencia, Spain, provides a whole-body medical imaging analysis. Quibim products are used worldwide by a huge diversity of research and care teams. Partners use Quibim Precision, a CE-marked whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers.

Ibex Medical Analytics develops AI-driven clinical decision support tools that help pathologists deliver more efficient, metric-driven, objective and accurate diagnosis. Ibex develops a diagnostic system that uses computer vision, machine learning, and electronic medical records to confirm cancer diagnoses of tissue biopsies. The company was founded in 2016 and is based in Israel.

Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.